ArticleJournal of clinical immunology2010
TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets.
Article in Journal of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Mannose-binding lectin 2 secreted by hepatocellular carcinoma cells recruits and activates natural killer cells to reshape an immune-activated microenvironment.PLoS biology · 2026Article
- TL1A and IL-18 synergy promotes GM-CSF-dependent thymic granulopoiesis in mice.Cellular & molecular immunology · 2024Article
- Article
- Article
- A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma.BioMed research international · 2022Article
- Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review.Frontiers in immunology · 2022Review
- An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma.Frontiers in oncology · 2022Article
- TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth.Oncoimmunology · 2022Article
- DR3 stimulation of adipose resident ILC2s ameliorates type 2 diabetes mellitus.Nature communications · 2020Article
- TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.Frontiers in immunology · 2019Review
- Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.Frontiers in immunology · 2018Review
- The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.Journal of leukocyte biology · 2015Review
- Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation.European journal of immunology · 2015Article
- Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients.Journal of translational medicine · 2015Article
- Immunobiology of TNFSF15 and TNFRSF25.Immunologic research · 2013Review
- Multiple activating and repressive cis-promoter regions regulate TNFSF15 expression in human primary mononuclear cells.Cytokine · 2013Article
- Article
- The role of TL1A and DR3 in autoimmune and inflammatory diseases.Mediators of inflammation · 2013Review
- TNFSF15 Modulates Neovascularization and Inflammation.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2012Article
- TLR9 and MyD88 are crucial for the development of protective immunity to malaria.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionTL1A (TNFSF15) augments IFN-gamma production by IL-12/IL-18 responsive human T cells. Its ligand, death domain receptor 3 (DR3), is induced by activation on T and NK cells. Although IL-12/IL-18 induces DR3 expression on most NK cells, addition of TL1A minimally increases IFN-gamma production.
methods(51)Chromium release and flow cytometric analysis were used to determine whether the TL1A-DR3 pathway is implicated in tumor cell lysis. Our aim was to determine whether the TL1A-DR3 pathway is implicated in tumor cell lysis.
resultsTL1A had no additional effect on IL-12/IL-18-induced cytotoxicity against an NK-susceptible tumor (K562); however, it promoted cytotoxicity against NK-resistant targets susceptible to lysis only by activated NK cells. DISCUSSION: With IL-12/IL-18 activation, TL1A increased CD107a expression on NK cells which led to enhanced lysis of Daudi by PBMC and purified NK cells. To a lesser degree, TL1A increased lysis of colorectal adenocarcinoma epithelial derived lines (WiDr and SW837) by IL-12/IL-18-activated cells.
conclusionTL1A increased cytotoxicity of IL-12/IL-18-activated NK cells against target cells dependent on NK activation for lysis and could function in vivo as a key co-activator of NK cytotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.